Press release
Glioblastoma Multiforme Market Overview: Major Segments, Strategic Developments, and Leading Companies
Glioblastoma Multiforme Market
Expected Market Growth and Valuation of the Glioblastoma Multiforme Market by 2030
The glioblastoma multiforme market is forecasted to expand significantly, reaching a valuation of $3.94 billion by 2030. This growth corresponds to a compound annual growth rate (CAGR) of 7.8%. Several factors contribute to this upward trajectory, including advancements in targeted drug development, an expanded focus on immunotherapy research, greater adoption of personalized cancer treatments, increased funding dedicated to brain cancer studies, and a stronger emphasis on improving patient survival outcomes. Key trends driving this growth include a heightened focus on targeted therapies, the use of multimodal treatment methods, ongoing progress in precision oncology research, widespread adoption of sophisticated imaging diagnostics, and enhanced participation in clinical trials.
Download a free report of the glioblastoma multiforme market report:
https://www.thebusinessresearchcompany.com/report/glioblastoma-multiforme-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR
Leading Companies Operating in the Glioblastoma Multiforme Market
The market features a number of prominent pharmaceutical and biotechnology firms actively developing and marketing therapies for glioblastoma multiforme. These industry leaders include Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Bristol Myers Squibb Company, AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Amgen Inc., Merck KGaA, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Zydus Pharmaceuticals (USA) Inc., Accord Healare Inc., Sumitomo Dainippon Pharma Oncology Inc., Karyopharm Therapeutics Inc., ITM Isotope Technologies Munich SE, Azurity Pharmaceuticals Inc., Genenta Science S.p.A., Chimeric Therapeutics Limited, and VBI Vaccines Inc.
A notable development in October 2024 saw Merck & Co., a US-based firm specializing in prescription medicines and vaccines, acquire Modifi Biosciences. This strategic acquisition aims to bolster Merck's oncology pipeline by integrating Modifi's innovative preclinical platform, which targets cancer cells with DNA repair deficiencies, including those lacking the MGMT protein. This platform shows promise against highly resistant tumors such as glioblastoma. Modifi Biosciences, based in the US, focuses on treatments specifically designed for glioblastoma multiforme.
View the full glioblastoma multiforme market report:
https://www.thebusinessresearchcompany.com/report/glioblastoma-multiforme-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR
Key Trends Positively Shaping the Glioblastoma Multiforme Market
Innovations in product development are playing a crucial role in strengthening market positions. For example, in January 2023, UK-based Lawton Tubes, a manufacturer and distributor specializing in medical gas copper pipelines, highlighted the benefits of copper in medical applications. Copper's natural antimicrobial properties help eliminate bacteria, fungi, and viruses, making it ideal for transporting oxygen and other medical gases in healare settings. Additionally, copper's recyclability supports environmental sustainability goals, aiding health systems in reducing their carbon footprint. During the pandemic, Lawton Tubes supplied copper pipelines to over 35 countries, showcasing copper's value in medical gas infrastructure.
Ongoing research and product innovation continue to drive interest in effective glioblastoma treatments, with a growing emphasis on combining sustainability with cutting-edge medical technology. This trend reinforces the market's positive momentum and encourages further investments.
Detailed Segment Analysis of the Glioblastoma Multiforme Market
The glioblastoma multiforme market is segmented comprehensively across multiple dimensions, providing a clear view of the various categories.
1) By Drug Class:
- Chemotherapy Agents
- Temozolomide
- Carmustine
- Lomustine
- Other Drug Classes
2) By Diagnostic Tools:
- Magnetic Resonance Imaging (MRI)
- Computed Tomography Scan (CT Scan)
- Biopsy
- Other Diagnostic Tools
3) By Treatment Type:
- Surgery
- Radiation Therapy
- Chemotherapy
- Immunotherapy
- Tumor Treating Field Therapy
- Other Treatment Types
4) By End-User:
- Hospitals
- Cancer Research Institutes
- Ambulatory Surgical Centers
- Other End-Users
Further subcategories under drug classes include:
- Chemotherapy Agents such as Alkylating Agents, Platinum-Based Agents, and Antimetabolites
- Temozolomide divided into Branded (Temodar) and Generic versions
- Carmustine available as Injectable Carmustine and Carmustine Wafers (Gliadel)
- Lomustine offered as Branded (Gleostine) and Generic Lomustine
- Other Drug Classes encompassing Targeted Therapy, Immunotherapy, and Tumor-Treating Fields (TTF) Therapy
This segmentation provides a detailed framework for understanding the glioblastoma multiforme market's structure and the various treatment and diagnostic options available to patients and healare providers.
Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Glioblastoma Multiforme Market Overview: Major Segments, Strategic Developments, and Leading Companies here
News-ID: 4480177 • Views: …
More Releases from The Business Research Company
Emerging Sub-Segments Transforming the Head and Neck Cancer (HNC) Market Landsca …
The head and neck cancer (HNC) market is set to experience substantial expansion in the coming years. Driven by technological advancements and innovative therapies, this sector is becoming increasingly vital in oncology care. Let's explore the market's projected growth, key players, emerging trends, and important segments shaping its future.
Projected Market Value and Growth Trajectory of the Head and Neck Cancer Market
The head and neck cancer market is anticipated…
Competitive Analysis: Leading Companies and New Entrants in the Hair Loss Telehe …
The hair loss telehealth market is on the verge of remarkable expansion as digital healare increasingly meets the specific needs of patients facing hair loss challenges. With advances in technology and growing consumer preference for convenient, personalized care, this sector is set to experience rapid growth in the coming years. Let's explore the market's current size, driving factors, key players, prevailing trends, and segmentation to understand its future trajectory.
Projected Market…
Key Factors and Emerging Trends Shaping the Gynecology Robotic Surgery Market La …
The field of gynecology is experiencing a technological transformation with the increasing integration of robotic surgery systems. These advancements are reshaping surgical procedures by improving precision and patient outcomes. To understand the trajectory of this market, we will explore its expected growth, key players, leading trends, and the main segments defining the industry.
Projected Market Size and Growth of the Gynecology Robotic Surgery Market
The gynecology robotic surgery market is…
Granulomatosis With Polyangiitis Treatment Market Overview, Key Trends, and Majo …
The granulomatosis with polyangiitis treatment market is poised for substantial growth in the coming years, driven by advancements in medical therapies and enhanced disease management strategies. This evolving sector is benefiting from innovative approaches that aim to improve patient outcomes and streamline treatment processes.
Projected Market Value and Growth Trajectory in Granulomatosis With Polyangiitis Treatment
The market for granulomatosis with polyangiitis treatment is forecasted to expand significantly, reaching a valuation…
More Releases for Glioblastoma
Key Trends Shaping the Future Glioblastoma Multiforme Market From 2025-2034: Adv …
Which drivers are expected to have the greatest impact on the over the glioblastoma multiforme market's growth?
The growing number of brain disorder cases is anticipated to boost the glioblastoma multiforme market in the coming years. A brain disorder is a condition that affects the brain's structure or function, leading to cognitive, emotional, or physical difficulties. The rise in brain disorder cases is attributed to factors such as an aging population,…
Glioblastoma Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Glioblastoma Pipeline Insight, 2024," report provides comprehensive insights about 195+ companies and 210+ pipeline drugs in Glioblastoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Glioblastoma Pipeline Report
* DelveInsight's Glioblastoma pipeline report depicts…
Glioblastoma Multiforme Market Insights, Forecast to 2031
"Glioblastoma Multiforme Market 2024,"
The objectives outlined in the report are multifaceted and aimed at offering a comprehensive understanding of the Glioblastoma Multiforme market dynamics. These objectives encompass a meticulous analysis and forecast of the market's dimensions, encompassing both its value and volume aspects. Additionally, the report seeks to discern and delineate the market shares held by major segments within the Glioblastoma Multiforme industry, providing stakeholders with a nuanced perspective on market…
Beyond Bravery - Bill Fitzpatrick's Fight Against Glioblastoma
Bill Fitzpatrick Jr, a retired sales professional from GE, has recently ventured into the world of writing with his debut book. Inspired by his experiences during taking care of his wife, who had Glioblastoma, Bill felt the need to share his journey and provide support to other families navigating similar challenges. In this article, we will dive into Bill's background, his motivation for becoming an author, details about his latest…
Recurrent Glioblastoma Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Recurrent Glioblastoma Pipeline Insight 2024" report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Recurrent Glioblastoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Recurrent Glioblastoma Pipeline Report
DelveInsight's Recurrent Glioblastoma…
Revolutionizing Glioblastoma Treatment Strategies: A Deep Dive into the Glioblas …
The Glioblastoma Pipeline Insight 2023 report by DelveInsight offers a thorough global overview of Glioblastoma treatments, including those already in the market, as well as those in different phases of clinical development. Prominent pharmaceutical firms are dedicated to progressing the Glioblastoma pipeline landscape and fostering the potential growth of Glioblastoma therapeutic advancements.
Key Takeaways from the Glioblastoma Pipeline Report
• DelveInsight's Glioblastoma pipeline report depicts a robust space with 195+ active players…
